Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): a multicentre, randomised, phase 2 trial
Oslo University Hospital · University of Oslo · +23 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
199
total citations
- FWCI
- 49.53
- Percentile
- 100%
- References
- 27
Citations per year
Authors
49- KJKnut Jørgen LaboriCorresponding
Oslo University Hospital, University of Oslo
- SOSvein Olav Bratlie
Sahlgrenska University Hospital, University of Gothenburg
- BABodil Andersson
Skåne University Hospital, Lund University
- JAJon‐Helge Angelsen
University of Bergen, Haukeland University Hospital
- CBChristina Biörserud
Sahlgrenska University Hospital, University of Gothenburg
Topics & keywords
Topics
Keywords
- FOLFIRINOX
- Medicine
- Oncology
- Randomized controlled trial
- Neoadjuvant therapy
- Pancreatic cancer
- Internal medicine
- Surgery
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.